Current drug discovery processes require assay formats

Transcription

1 Homogeneous GTP Binding Assay Employing RET Technology ANITA ROZWANDOWICZ-JANSEN, 1 JONNE LAURILA, 2,4 EIJA MARTIKKALA, 1 HEINI FRANG, 3 ILKKA HEMMILÄ, 3 MIKA SCHEININ, 2 PEKKA HÄNNINEN, 1 and HARRI HÄRMÄ 1 Functional cell signaling assays have become important tools for measuring ligand-induced receptor activation in cell-based biomolecular screening. Guanosine-5 -triphosphate (GTP) is a generic signaling marker responsible for the first intracellular signaling event of the G-protein-coupled receptors (GPCRs). [ 35 S]GTPγS binding assay is the classical well-established method for measuring agonist-induced G-protein activation requiring a separation of free and bound fractions prior to measurement. Here a novel, separation-free, time-resolved fluorescence GTP binding assay has been developed based on a non fluorescence resonance energy transfer (FRET) single-label approach and quenching of a nonbound europium-labeled, nonhydrolyzable GTP analog (Eu-GTP). The quenching resonance energy transfer (RET) method relies on the use of Eu-GTP, providing a time-resolved fluorescent detection as an alternative to the radiolabel [ 35 S]GTPγS assay. Upon activation of recombinant human α 2A -adrenoceptors (α 2A -AR) expressed in Chinese hamster ovary cells, guanosine-5 -diphosphate is released from the α-subunit of Gi-proteins, enabling the subsequent binding of Eu-GTP. Activation of α 2A -AR with 5 different α 2 -AR agonists was measured quantitatively using the developed RET GTP assay and compared to [ 35 S]GTPγS and heterogeneous Eu-GTP filtration assays. Equal potencies and efficacy rank orders were observed in all 3 assays but with a lower signal-to-background ratio and increased assay variation in the RET assay compared to the Eu-GTP filtration and the nonhomogeneous [ 35 S]GTPγS binding assays. (Journal of Biomolecular Screening 2010: ) Key words: GTP binding assay, functional cell-based assay, time-resolved fluorescence, homogeneous assay, RET Introduction Current drug discovery processes require assay formats that are in general simple and inexpensive to perform. Many of these are driven by the increasing cost in the health care sector. High-throughput screening (HTS) has become an integral part of the drug discovery process, 1 with the driving force toward simplification, cost reduction, assay automation, and miniaturization, which is indispensable for screening larger and more diverse compound libraries. G-protein-coupled receptors (GPCRs) represent one of the largest protein superfamilies in the human genome. These membrane-bound cell surface receptors mediate the effects of a wide variety of endogenous and exogenous ligands and regulate many important cellular responses. GPCRs are involved in 1 Laboratory of Biophysics, Institute of Biomedicine, University of Turku, Finland. 2 Department of Pharmacology, Drug Development and Therapeutics, Institute of Biomedicine, University of Turku, and TYKSLAB, Turku University Hospital, Turku, Finland. 3 PerkinElmer, Wallac Oy, Turku, Finland. 4 Drug Discovery Graduate School, University of Turku, Finland. Received Jul 3, 2009, and in revised form Oct 23, Accepted for publication Nov 22, Journal of Biomolecular Screening 15(3); 2010 DOI: / many physiological processes, and their dysfunctions have been associated with various common diseases. The location of GPCRs in the plasma membrane makes them extremely attractive targets for pharmaceuticals (i.e., it is estimated that about 40%-50% of the current clinically used drugs act on GPCRs). 2 The GPCRs closely associate with the G-protein subunits Gα (39-46 kda) and the 36- to 37-kDa β and 5- to 10-kDa γ subunit (Gβγ) dimer. At agonist activation, a conformational change of a GPCR promotes binding of guanosine-5 -triphosphate (GTP) to the Gα subunit in exchange for guanosine-5 - diphosphate (GDP). 3-6 Guanine nucleotide exchange is an early intracellular event in the signal transduction process, being a generic indicator for signaling to all GPCRs. The radiolabelbased [ 35 S]GTPγS binding assay is widely used to implicate such a signaling process. The [ 35 S]GTPγS binding assay measures the level of agonist-activated GPCR activation by determining the binding of the nonhydrolyzable [ 35 S]GTPγS analog to the G-protein α-subunit. 7,8 Time-resolved fluorometry (TRF) is a well-established alternative technology to radioisotopic assays in many highthroughput applications. 9 The use of TRF has already been described for measuring G-protein activation of, for example, human α 2A -adrenergic, 10 cytokine, 11 muscarinic, 12 dopamine, 13,14 opioid, 15 and serotonin 16,17 receptors. Receptor activation was assessed by measuring the binding of a europium-labeled GTP analog (Eu-GTP) to Gα protein on cell membranes. This highly 2010 Society for Biomolecular Sciences 261

2 Rozwandowicz-Jansen et al. sensitive, nonradioactive functional method potentially improves the screening processes as problems related to waste and storage of radioactive materials can be omitted. However, a separation of bound and nonbound Eu-GTP must still be carried out using filtration or washing. 10 We have explored the use of novel, homogeneous assay formats based on the single time-resolved fluorescence label strategy and a nonspecific quenching mechanism (quenching resonance energy transfer [RET] technique). The first demonstration of the quenching assay principle shows the potential of the method for receptor-ligand binding studies in drug discovery. 18 The RET technique is a novel separation-free assay method based on time-resolved fluorescence detection technology using lanthanide(iii) chemistry and soluble fluorescence quenchers at the lanthanide(iii) emission wavelength. Here we describe the use of the RET technology for monitoring the activation of GPCRs in a GTP binding assay. We compared the new method with 2 previously established heterogeneous GTP binding assays: [ 35 S]GTPγS and nonradioactive Eu-GTP assays. 7,8,10 Materials Materials and Methods [Ethyl- 3 H]RS (specific activity 81 Ci/mmol) was obtained from GE Healthcare Life Sciences (Buckinghamshire, UK). [ 35 S]GTPγS (specific activity 1250 Ci/mmol) was obtained from PerkinElmer Life and Analytical Sciences (Boston, MA). ( )-Epinephrine, clonidine, ( )-norepinephrine, oxymetazoline, brimonidine, bovine serum albumin (BSA), and 1,1,3,3,3,3 - hexamethylindodicarbocyanine iodide were purchased from Sigma-Aldrich (St. Louis, MO). Cell culture reagents were supplied by GIBCO (Invitrogen Life Technologies, Inc., Rockville, MD), and fetal bovine serum was from Autogen Bioclear UK Ltd. (Wiltshire, UK). Other reagents were of analytical or reagent grade and were purchased from commercial suppliers. GDP, MgCl 2, NaCl, 50 mm HEPES (ph 7.4), and GTP wash solution were obtained from PerkinElmer, Wallac (Turku, Finland). AcroWell 96-well filter membrane bottom plates (GHP membrane) were from Pall Life Sciences (East Hills, NY), and black 96-well plates were obtained from PerkinElmer. Eu-labeled GTP was guanosine-5 -triphosphate coupled with a fluorescent chelate, 19 obtained from PerkinElmer s DELFIA GTP Binding Kit. Cell culture A Chinese hamster ovary (CHO) cell line stably expressing the cdna encoding human α 2A -adrenoceptors was produced as described by Pohjanoksa et al. 20 Cells were cultured in α Minimum Essential Medium (α-mem) supplemented with 26 mm NaHCO 3, 50 U/mL penicillin, 50 μg/ml streptomycin, and 5% heat-inactivated fetal bovine serum supplemented with 200 μg/ml of the neomycin analog G418 (Geneticin ; Sigma- Aldrich). Cells were grown in a humidified incubator at 37 C/5% CO 2. Membrane preparation Cell membranes were prepared as previously described. 20 Membranes were suspended in 10 mm Tris buffer (ph 7.5) containing 0.1 mm EDTA and aliquoted and stored at 74 C. Protein concentrations were determined according to the method of Bradford 21 using bovine serum albumin as reference. Saturation binding assay Receptor density of CHO cells expressing human α 2A - adrenoceptor was determined with saturation binding experiments as described previously, 22 using the α 2 -antagonist radioligand [ethyl- 3 H]RS ( nm). Experiments were performed in triplicate and repeated 3 times. Equilibrium dissociation constant (K d ) and receptor density (B max ) were calculated from saturation binding data using GraphPad Prism Software (San Diego, CA). GTP binding assays A homogeneous GTP binding assay based on the RET technique was developed and compared to well-known heterogeneous [ 35 S]GTPγS and time-resolved fluorescence filtration GTP binding assays. EC 50, E max, and signal-to-background ratios (the signal obtained in the presence of an agonist concentration causing a maximal response/the background signal from the system containing no agonist) were calculated in the comparative tests. Heterogeneous [ 35 S]GTPγS binding assay. Agonist-induced stimulation of [ 35 S]GTPγS binding was measured essentially as described previously. 23 Briefly, membranes were thawed and resuspended in incubation buffer (50 mm Tris, 1 mm EDTA, 5 mm MgCl 2, 20 mm NaCl, 1 μm GDP, 1 mm dithiothreitol [DTT], 30 μm ascorbic acid, ph 7.4). All incubations were performed on 96-well Millipore MultiScreen MAFB/MSFB glass fiber filter plates (Millipore Corp., Bedford, MA). Samples containing 5 μg of membrane protein were incubated with agonists and 0.1 nm [ 35 S]-GTPγS for 30 min at 37 C. Reactions were terminated by vacuum filtration using a Millipore MultiScreen Vacuum Manifold. The filter plates were washed 3 times with ice-cold wash buffer (20 mm Tris, 1 mm EDTA, 5 mm MgCl 2, ph 7.4). Filters were dried, and 50 μl SuperMix scintillation cocktail (PerkinElmer, Wallac) was added into each well. The incorporated radioactivity was measured using a MicroBeta scintillation counter (PerkinElmer, Wallac). All assays were performed in duplicate. Additional [ 35 S]GTPγS control experiments were performed with the Journal of Biomolecular Screening 15(3); 2010

3 Homogeneous GTP Binding Assay Employing RET Technology soluble quencher (1,1,3,3,3,3 -hexamethylindodicarbocyanine iodide) that was used in the homogeneous RET assay to test whether the quencher affected the binding properties of [ 35 S] GTPγS in the assay. The quencher (2.3 μm) was added upon completion of the [ 35 S]GTPγS incubation step and 5 min before vacuum filtration. This simulated the procedure of the homogeneous RET assay. Heterogeneous time-resolved fluorescence assay. The Eu-GTP binding assay was performed in AcroWell filter plates using a 2-step incubation protocol. The reaction was started by adding an aliquot of the membrane suspension (10 μg protein) to reaction buffer containing 50 mm HEPES buffer, ph 7.4, supplemented with 50 mm NaCl, 5 mm MgCl 2, 2.5 μm GDP, and varying concentrations of the following agonists to a total volume of 100 μl: ( )-epinephrine, clonidine, ( )-norepinephrine, oxymetazoline, and brimonidine. After a 30-min preincubation on a plate shaker (slow shaking), 10 nm europiumlabeled GTP was added. Incubation was continued for another 30 min, and the reaction was terminated by vacuum filtration (MultiScreen Vacuum Manifold, Millipore), followed by 2 washes with ice-cold buffer (50 mm Tris-HCl, ph 7.5, 10 mm MgCl 2 ). The bound Eu-GTP was measured immediately after filtration with a Victor 2 fluorescent plate reader (PerkinElmer, Wallac). The delay and integration times were 400 μs, and the excitation and emission wavelengths were 340 and 615 nm, respectively. Homogeneous RET assay. CHO cell membranes (30 μg protein) were dispensed into 96-well plates in 50 mm HEPES, ph 7.4. Agonists were added at varying concentrations to a total volume of 100 μl in the reaction buffer (50 mm HEPES, ph 7.4; 2.5 μm GDP; 5 mm MgCl 2 ; 50 mm NaCl; 0.001% BSA) and incubated for 30 min at room temperature in the dark with slow shaking. Thereafter, 10 μl of Eu-GTP (final concentration 10 nm) was added, and the reaction mixture was incubated for another 30 min under the same conditions. After incubation, 20 μl of soluble quencher (1,1,3,3,3,3 - hexamethylindodicarbocyanine iodide) at 15 μm concentration (final concentration 2.3 μm) was added, the plate was shaken, and time-gated fluorescence was measured with a Victor 2 fluorescent plate reader. The delay and integration times were 400 μs, and the excitation and emission wavelengths were 340 and 615 nm, respectively. Saturation binding assay Results and Discussion The receptor density (B max ) determined with 3 independent saturation binding experiments was 3800 ± 60 fmol/mg of protein for CHO cell membranes stably expressing human α 2A -AR. The equilibrium dissociation constant (K d ) of the radioligand [ethyl- 3 H]RS was 0.11 ± 0.01 nm. Homogeneous RET assay A simple homogeneous nonradioactive RET assay for GTP binding was developed using a single-label approach and quenching of time-resolved luminescence in solution (Fig. 1). With agonist-induced activation of α 2A -AR in CHO cell membranes and subsequent binding of Eu-labeled GTP to Gαi protein, the fluorescence of Eu-GTP was protected and measured at 615 nm. When no receptor activation was carried out, Eu-GTP remained in solution, and nonbound Eu-GTP was quenched in solution using 1,1,3,3,3,3 -hexamethylindodicarbocyanine iodide at 2.3 μm quencher concentration. The developed assay was performed on 96-well plates to compare the results with previously validated [ 35 S]GTPγS and Eu-GTP 96-plate filtrations assays. The RET assay was conducted in 2 steps: 30-min agonist preincubation and 30-min incubation with Eu-GTP, as well as subsequent addition of the quencher and detection of the time-gated Eu(III) luminescence signal. The assay conditions of the homogeneous RET assay were chosen based on our previous optimized assay conditions. 10 However, the composition of the reaction buffer was modified by adding 0.001% BSA to reduce any possible nonspecific binding. In the employed [ 35 S]GTPγS binding assay, the concentrations of GDP and NaCl markedly affect the stimulation efficacy and signal-to-background ratio of [ 35 S]GTPγS binding. High concentrations of GDP (10 μm) or NaCl (150 mm) effectively decrease the stimulation efficacy of partial agonists. 10 Therefore, in the present study, the GDP and NaCl concentrations were chosen not to exceed these concentrations. For the homogeneous RET assay, the quantity of membrane protein in the sample was optimized, varying from 10 to 60 μg per well in norepinephrine-induced stimulations (Fig. 2). Agonist-stimulated binding of Eu-GTP was detectable already at 10 μg membrane protein, but the signal-tobackground ratio was insufficient. With 30 μg membrane protein, the signal-to-background ratio was 2, reaching an apparent saturation. Thus, 30 μg membrane was chosen for further experiments. Dose-response experiments were carried out under the optimized assay conditions for 5 agonists that are full or partial agonists at α 2A -AR: ( )-norepinephrine, ( )-epinephrine, brimonidine, clonidine, and oxymetazoline (Fig. 3a). EC 50 and E max values were calculated from the dose-response data and are given in Table 1. The signal-to-background ratio for ( )-norepinephrine was 1.9, and the average coefficient of variation was 13.1% for the different agonists. The quencher was found to have an insignificant effect on assay performance, as studied with the radioligand [ 35 S]GTPγS assay (data not shown). Journal of Biomolecular Screening 15(3);

4 Rozwandowicz-Jansen et al. Added substances α2-ar CHO cell membrane G protein GDP Agonist GTP Eu Low signal High signal Agonist GTP Eu G protein Agonist G protein GTP Eu FIG. 1. The principle of the homogeneous Eu-GTP binding assay using the quenching resonance energy transfer (RET) principle. Signal-to-background ratio Membrane protein (µg) FIG. 2. Optimization of the membrane protein concentration in the homogeneous quenching resonance energy transfer (RET) assay. After agonist exposure, a significant difference between the basal and agonist-induced binding was observed for all tested agonists. The full agonists resulted in a higher efficacy compared with the partial agonists showing a reduced basal binding activity. Brimonidine has been reported to have a lower efficacy than ( )-norepinephrine and ( )-epinephrine, as observed here too. Heterogeneous time-resolved fluorescence assay Heterogeneous nonradioactive assays were performed using the commercially available test kit. 10 The reaction conditions were the same as in the new homogeneous assay system, excluding BSA and using only 10 μg membrane protein. After the 2-step incubation, nonbound Eu-GTP was separated using filtration on a vacuum manifold. The full and partial agonists were investigated in this heterogeneous assay format, and the dose-response curves are shown in Figure 3b. Generally, in comparison to the homogeneous assay format, similar rank orders of efficacy and potency were observed. However, the maximal binding efficacies (E max ) of the full agonist were higher than in the homogeneous assay format (Table 1). The average coefficient of variation was 8.6% for the different agonists, and the signal-to-background ratio of 3.3 was obtained for ( )-norepinephrine Journal of Biomolecular Screening 15(3); 2010

5 Homogeneous GTP Binding Assay Employing RET Technology Over basal % Over basal % Over basal % a) GTPγS 250 b) Eu-GTP filtration c) Eu-GTP RET Agonist concentration (nm) FIG. 3. Dose-response curves of guanosine-5 -triphosphate (GTP) binding assays: (a) heterogeneous GTPγS, (b) heterogeneous Eu-GTP filtration, and (c) homogeneous quenching resonance energy transfer (RET) assays. Five known agonists ( ) ( )-norepinephrine, ( ) ( )-epinephrine, ( ) brimonidine, ( ) clonidine, and ( ) oxymetazoline were investigated in Chinese hamster ovary (CHO) cell membranes expressing recombinant human α 2A -adrenoceptors. Heterogeneous [ 35 S]GTPγS binding assay Radiolabel binding assays are well established in biomolecular screening laboratories; therefore, an in-house developed [ 35 S]GTPγS binding assay was chosen for comparison. 23 The assay conditions differed from the nonradioactive binding assays as the buffer constitution was different (Tris vs. HEPES), and only 5 μg of membrane protein was used. After incubation, the reaction mixture was vacuum filtered through a glass fiber filter to separate nonbound [ 35 S]GTPγS from the bound fraction. For the radiolabeled-based [ 35 S]GTPγS binding assay, previously similar high efficacy has been reported for the full agonists ( )-norepinephrine, ( )-epinephrine, and brimonidine, as observed in the present study. 10 The signal-to-background ratio for ( )-norepinephrine was 5.5, which was clearly higher than that for the nonradioactive methods. Of the tested methods, the [ 35 S]GTPγS binding assay is by far the most established method, resulting in the lowest coefficient of variation, 1.9%. Comparison of the methods The comparison of the methods was based on the characteristics of the dose-response data. The evaluation of the halfmaximal effective concentration EC 50 and the maximal binding efficacy E max is given in Table 1. The EC 50 values of 2 endogenous agonists ( )-norepinephrine and ( )-epinephrine as determined in the RET homogeneous Eu-GTP binding assay were somewhat lower than the corresponding values in the radiolabel and heterogeneous, nonradioactive binding assays. The EC 50 value of brimonidine was the same independently of the method used. The EC 50 values of clonidine and oxymetazoline may not be directly comparable as the signal-to-background ratios of the partial agonists were generally weak, and relatively high assay variation was observed. The rank orders of agonist efficacy were very similar in all assay formats. However, differences in the E max values and signal-to-background ratios were measured (Table 1). The well-established [ 35 S]GTPγS assay resulted in the highest signal-to-background ratio and the homogeneous Eu-GTP the lowest. This suggests that the Eu-GTP binding may potentially be weaker than that of the radiolabeled GTP. The concentration of membrane protein required per assay was 2-fold higher for the heterogeneous and 6-fold for the homogeneous Eu-GTP assay than that of the GTPγS assay, which also partially supports the weaker binding property of Eu-GTP. The assay variation was very low in the [ 35 S]GTPγS assay. The [ 35 S]GTPγS was well established in our hands in comparison with the TRF Eu-GTP filtration assay. The TRF Eu-GTP filtration assay was carried out in the Laboratory of Biophysics during this study for the first time, which may have resulted in the higher variation of the Eu-GTP assay. Evidently, more work needs to be carried out to improve the reproducibility of the RET Eu-GTP assay, and automation of the manual Eu-GTP assay may have to be established. Journal of Biomolecular Screening 15(3);

6 Rozwandowicz-Jansen et al. Table 1. Characterization of the GTP Binding Assays Method [ 35 S]-GTPγS Eu-GTP filtration RET Assay Assay format Heterogeneous Heterogeneous Homogeneous Detection Radioactivity TRF TRF Membrane protein, μg Agonist EC 50, nm E max, % over Basal EC 50, nm E max, % over Basal EC 50, nm E max, % over Basal ( )-Norepinephrine ( )-Epinephrine Brimonidine Clonidine Oxymetazoline Three methods were investigated for their assay parameters at agonist activation of recombinant human α 2A -adrenoceptors overexpressed in Chinese hamster ovary cell membranes. GTP, guanosine-5 -triphosphate; RET, quenching resonance energy transfer; TRF, time-resolved fluorometry. Conclusions A homogeneous assay based on the RET technique was developed for the GTP binding assay. The developed assay was compared with the heterogeneous [ 35 S]GTPγS and Eu-GTP binding assays at stimulation of α 2 -AR on CHO cell membranes with comparable efficacy rank order and EC 50 values. The [ 35 S]GTPγS assay resulted in the lowest assay variation and the highest signal-to-background ratio of the methods. Although further fine-tuning of the assay parameters, possibly through new synthetic strategies of the Eu-labeled GTP, is required in the homogeneous RET method, this study shows the potential of the single-label time-resolved fluorescence concept in assaying old targets with a novel means. As there is no need to label the target receptor in the RET technique, this additional free dimension allows the development of new nonradioactive technologies for drug discovery purposes. Acknowledgments The work was supported by the Finnish Funding Agency for Technology and Innovation, Tekes. References 1. Landro JA, Taylor IC, Stirtan WG, Osterman DG, Kristie J, Hunnicutt EJ, et al: HTS in the new millennium: the role of pharmacology and flexibility. J Pharmacol Toxicol Methods 2000;44: Lundstrom K: Structural genomics of GPCRs. Trends Biotechnol 2005;23: Kristiansen K: Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function. Pharmacol Ther 2004;103: Birnbaumer L: G proteins in signal transduction. Annu Rev Pharmacol Toxicol 1990;30: Gilman AG: G proteins: transducers of receptor-generated signals. Annu Rev Biochem 1987;56: Pfeuffer T, Helmreich EMJ: Structural and functional relationships of guanosine triphosphate binding proteins. Curr Topics Cellular Regulation 1988;29: Milligan G: Principles: extending the utility of [ 35 S] GTP gamma S binding assays. Trends Pharmacol Sci 2003;24: Harrison C, Traynor JR: The [ 35 S] GTP gamma S binding assay: approaches and applications in pharmacology. Life Sci 2003;74: Hemmilä I, Mukkala VM: Time-resolution in fluorometry technologies, labels, and applications in bioanalytical assays. Crit Rev Clin Lab Sci 2001;38: Frang H, Mukkala VM, Syystö R, Ollikka P, Hurskainen P, Scheinin M, et al: Nonradioactive GTP binding assay to monitor activation of G proteincoupled receptors. Assay Drug Dev Technol 2003;1: Labrecque J, Anastassov V, Lau G, Darkes M, Mosi R, Fricker SP: The development of an europium-gtp assay for quantitate chemokine antagonist interactions for CXCR4 and CCR5. Assay Drug Dev Technol 2005;3: Zhang H-Y, Watson ML, Gallagher M, Nicolle MM: Muscarinic receptormediated GTP-Eu binding in the hippocampus and prefrontal cortex is correlated with spatial memory impairment in aged rats. Neurobiol Aging 2007;28: Zhang M, Ballard ME, Unger LV, Haupt A, Gross G, Decker MW, et al: Effects of antipsychotics and selective D 3 antagonists on PPI deficits induced by PD and apomorphine. Behav Brain Res 2007;182: Hsien GC, Hollingsworth PR, Martino B, Chang R, Terranova MA, O Neill AB, et al: Central mechanisms regulating penile erection in conscious rats: the dopamine systems related to the preerectile effect of apomorphine. J Pharmacol Exp Ther 2004;308: Markkanen PMH, Petäjä-Repo UE: N-Glycan-mediated quality control in the endoplasmic reticulum is required for the expression of correctly folded delta-opioid receptors at the cell surface. J Biol Chem 2008;283: Meregheti I, Cagnotto A, Mennini T: Dimethyl sulfoxide: an antagonist in scintillation proximity assay [ 35 S]-GTPγS binding to rat 5-HT 6 receptor cloned in HEK-293 cells? J Neurosci Methods 2007;160: Cornelius P, Lee E, Lin W, Wang R, Werner W, Brown JA, et al: Design, synthesis, and pharmacology of fluorescently labeled analogs of serotonin: Journal of Biomolecular Screening 15(3); 2010

7 Homogeneous GTP Binding Assay Employing RET Technology application to screening of the 5-TH 2C receptor. J Biomol Screen 2009; 14: Härmä H, Rozwandowicz-Jansen A, Martikkala E, Frang H, Hemmilä I, Sahlberg N, et al: A new simple cell-based homogeneous time-resolved fluorescence RET technique for receptor-ligand interaction screening. J Biomol Screen 2009;14: Hemmilä IA, Hurskainen P: Novel detection strategies for drug discovery. Drug Discov Today 2002;7:S150-S Pohjanoksa K, Jansson CC, Luomala K, Marjamäki A, Savola J-M, Scheinin M: α 2 -Adrenoceptor regulation of adenylyl cyclase in CHO cells: dependence on receptor density, receptor subtype and current activity of adenylyl cyclase. Eur J Pharmacol 1997;335: Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem 1976;72: Halme M, Sjöholm B, Savola JM, Scheinin M: Recombinant human alpha2-adrenoceptor subtypes: comparison of [3H]rauwolscine, [3H]atipamezole and [3H]RX as radioligands. Biochim Biophys Acta 1995;1266: Peltonen JM, Pihlavisto M, Scheinin M: Subtype-specific stimulation of [ 35 S]GTPgammaS binding by recombinant alpha2-adrenoceptors. Eur J Pharmacol 1998;355: Address correspondence to: Anita Rozwandowicz-Jansen University of Turku Laboratory of Biophysics Tykistökatu 6A, 5th Floor, Turku 20520, Finland aniroz@utu.fi Journal of Biomolecular Screening 15(3);